索引于
  • 学术期刊数据库
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 研究圣经
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • 学者指导
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Leveraging Lymphoblastoid Cell Lines for Drug Response Modeling

Alison A Motsinger-Reif1,2 and Daniel M Rotroff1,2*

Lymphoblastoid cell lines (LCL) are becoming popular tools for modeling drug response. LCLs, and other in vitro assays, offer the ability to test many drugs, doses, and biological samples relatively quickly and inexpensively. In addition, a unique advantage to LCLs is that they are available from a large cohort of individuals, providing the capability to test for genetic variability on a scale not readily available in other in vitro systems. Since oftentimes the genotype data is publically available, the experimental costs can be limited to the cost of the drug response phenotyping. Here we describe several advantages and limitations of LCLs. In addition we review several important aspects of LCL experimental design and statistical analysis. Lastly, we present an example of LCLs being successfully used to identify candidate single nucleotide polymorphisms and genes for variability in response to a chemotherapeutic used to treat chronic myeloid leukemia.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证